Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7770

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500907770)

Label Image (Lbl500907770)
Levetiracetam 1000 mg film coated tablets label from A-S Medication Solutions. The label states each film-coated tablet contains 1000 mg of levetiracetam, with a package count of 180 tablets. Storage instructions indicate keeping the tablets at 68 to 77 degrees Fahrenheit. The label includes NDC 50090-7770-2 and barcode details for dispensing.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
Bar graph showing responder rates with at least 50% reduction from baseline in Study 1. It compares placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%) groups, with responder percentages on the vertical axis and treatment groups on the horizontal axis. Asterisks indicate statistical significance versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
Bar chart showing responder rates with 50% or greater reduction from baseline in Study 2 Period A. The y-axis represents the percentage of patients. Results show placebo at 6.3%, Levetiracetam 1000 mg/day at 20.8%, and Levetiracetam 2000 mg/day at 35.2%, with asterisks indicating statistical significance versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' showing the percentage of patients responding. The chart compares placebo (N=104) with 14.4% responder rate against Levetiracetam 3000 mg/day (N=180) with 39.4% responder rate, noting statistical significance versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
Bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' showing percentage of patients for placebo and Levetiracetam. Placebo group (N=97) has about 19.6% responders, while Levetiracetam group (N=101) has about 44.6% responders, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
Bar chart showing responder rates for patients aged 1 month to less than 4 years achieving at least 50% reduction from baseline in Study 5, comparing Placebo and Levetiracetam. Levetiracetam group shows approximately 43.1% responders versus 19.6% for Placebo, indicating statistical significance.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
Bar chart showing responder rate (≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7. It compares placebo (45.2% of patients) with Levetiracetam (72.2% of patients), indicating a statistically significant improvement with Levetiracetam.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure diagram of levetiracetam, showing its molecular components and bonding arrangement as commonly represented in pharmaceutical labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.